EIKN — EIKON THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
EIKN FAQ
What is EIKN's ROE?
EIKON THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -53.71%.
What is EIKN's dividend yield?
EIKON THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is EIKN's Deepscope Quality Score?
Deepscope rates EIKN's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EIKN?
Deepscope's AI Timing Score for EIKN is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EIKN belong to?
EIKON THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.36
Price
-0.41
(-4.68%)
Day Change
|
|
|---|
EIKN Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.36 |
| PBV / Sector |
0.86 / 4.79
GREAT
|
| Earning Per Share | -5.21 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
3.54 M
GREAT
|
| Average 1W Daily Value |
1.89 M
GREAT
|
| Yếu tố Kỹ thuật |
|
14% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
37% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-11 09:55:02 |
| Symbol | EIKN |
| Name | EIKON THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 54.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 474.80 / 8,963.32 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 230 Harriet Tubman Way, Millbrae, CA, United States, 94030
Phone: 341 777 0566
Website: https://eikontx.com
Employees: 384
Sector: Healthcare >> Biotechnology
Description: Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google